Press "Enter" to skip to content

Merck, Pfizer drug combo extends kidney cancer survival: study

(Reuters) – A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study …

Please follow and like us:

Comments are closed.